Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells

Gene Therapy

Volumn 14, Issue 10, 2007, Pages 814-827

  Li, L ^a   Yang, L ^a   Scudiero, D A ^b   Miller, S A ^c   Yu, Z X ^a   Stukenberg, P T ^c   Shoemaker, R H ^b   Kotin, R M ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HIGHLY EXPRESSED IN CANCER PROTEIN 1; KINETOCHORE ASSOCIATED PROTEIN 2; NUCLEAR PROTEIN; PARVOVIRUS VECTOR; SHORT HAIRPIN RNA HIGHLY EXPRESSED IN CANCER PROTEIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL ACTIVATION; CELL DEATH; CENTROMERE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEPIDOPTERA; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SOLID TUMOR; TUMOR CELL LINE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE, TUMOR; DEPENDOVIRUS; FLOW CYTOMETRY; GENE DELETION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; KINETOCHORES; MICE; MICE, MUTANT STRAINS; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

ADENO-ASSOCIATED VIRUS; INVERTEBRATA; SPODOPTERA FRUGIPERDA;

EID: 34248177933     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302933     Document Type: Article

References (43)

1. Cheng JC, Moore TB, Sakamoto KM. RNA interference and human disease. Mol Genet Metab 2003; 80: 121-128.
2. Fuchs U, mm-Welk C, Borkhardt A. Silencing of disease-related genes by small interfering RNAs. Curr Mol Med 2004; 4: 507-517.
3. Heidenreich O. Oncogene suppression by small interfering RNAs. Curr Pharm Biotechnol 2004; 5: 349-354.
4. it-Si-Ali S, Guasconi V, Harel-Bellan A. RNA interference and its possible use in cancer therapy. Bull Cancer 2004; 91: 15-18.
5. Poliseno L, Mercatanti A, Citti L, Rainaldi G. RNA-based drugs: From RNA interference to short interfering RNAs. Curr Pharm Biotechnol 2004; 5: 361-368.
6. Scherer L, Rossi JJ. Recent applications of RNAi in mammalian systems. Curr Pharm Biotechnol 2004; 5: 355-360.
7. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002; 20: 500-505.
8. Miyagishi M, Taira K. U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 2002; 20: 497-500.
9. Sui G, Soohoo C, Affar eB, Gay F, Shi Y, Forrester WC et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 5515-5520.
10. Mailand N, Lukas C, Kaiser BK, Jackson PK, Bartek J, Lukas J. Deregulated human Cdc14A phosphatase disrupts centrosome separation and chromosome segregation. Nat Cell Biol 2002; 4: 317-322.
11. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 1443-1448.
12. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
13. Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 6047-6052.
14. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296 550-553.
15. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102: 5820-5825.
16. Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003; 33: 396-400.
17. Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 2003; 22: 5712-5715.
18. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10: 816-820.
19. Ciferri C, De LJ, Monzani S, Ferrari KJ, Ristic D, Wyman C et al. Architecture of the human ndc80-hec1 complex, a critical constituent of the outer kinetochore. J Biol Chem 2005; 280: 29088-29095.
20. DeLuca JG, Dong Y, Hergert P, Strauss J, Hickey JM, Salmon ED et al. Hec1 and nuf2 are core components of the kinetochore outer plate essential for organizing microtubule attachment sites. Mol Biol Cell 2005; 16: 519-531.
21. DeLuca JG, Howell BJ, Canman JC, Hickey JM, Fang G, Salmon ED. Nuf2 and Hec1 are required for retention of the checkpoint proteins Mad1 and Mad2 to kinetochores. Curr Biol 2003; 13: 2103-2109.
22. Kline-Smith SL, Sandall S, Desai A. Kinetochore-spindle microtubule interactions during mitosis. Curr Opin Cell Biol 2005, 17: 35-46.
23. McCleland ML, Kallio MJ, Barrett-Wilt GA, Kestner CA, Shabanowitz J, Hunt DF et al. The vertebrate Ndc8O complex contains Spc24 and Spc25 homologs, which are required to establish and maintain kinetochore-microtubule attachment. Curr Biol 2004; 14: 131-137.
24. Stucke VM, Baumann C, Nigg EA. Kinetochore localization and microtubule interaction of the human spindle checkpoint kinase Mps1. Chromosoma 2004; 113: 1-15.
25. Emanuele MJ, McCleland ML, Satinover DL, Stukenberg PT. Measuring the stoichiometry and physical interactions between components elucidates the architecture of the vertebrate kinetochore. Mol Biol Cell 2005; 16: 4882-4892.
26. Bharadwaj R, Qi W, Yu H. Identification of two novel components of the human NDC80 kinetochore complex. J Biol Chem 2004; 279: 13076-13085.
27. Chen Y, Riley DJ, Zheng L, Chen PL, Lee WH. Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem 2002; 277: 49408-49416.
28. Gurzov EN, Izquierdo M. RNA interference against Hec1 inhibits tumor growth in vivo. Gene Ther 2006; 13: 1-7.
29. McCarty DM, Young Jr SM, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004; 38: 819-845.
30. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
31. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
32. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001; 75: 6884-6893.
33. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 2006; 80: 9831-9836.
34. Hacker UT, Wingenfeld L, Kofler DM, Schuhmann NK, Lutz S, Herold T et al. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gene Med 2005; 7: 1429-1438.
35. Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol 2003; 77: 7034-7040.
36. Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: Implications for the treatment of prostate cancer. FASEB J 2005; 19: 611-613.
37. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100: 5789-5794.
38. Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U et al. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 2004; 25: 1065-1071.
39. Guan HT, Xue XH, Dai ZJ, Wang XJ, Li A, Qin ZY. Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J Gastroenterol 2006; 12: 2901-2907.
40. Mirza A, Basso A, Black S, Malkowski M, Kwee L, Pachter JA et al. RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis. Cancer Biol Ther 2005; 4: 1355-1360.
41. Miyagishi M, Sumimoto H, Miyoshi H, Kawakami Y, Taira K. Optimization of an siRNA-expression system with an improved hairpin and its significant suppressive effects in mammalian cells. J Gene Med 2004; 6: 715-723.
42. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13 1935-1943.
43. Li L, Yang L, Kotin RM. The DNA minor groove binding agents Hoechst 33258 and 33342 enhance recombinant adeno-associated virus (rAAV) transgene expression. J Gene Med 2005; 7: 420-431.